Estrogen Receptor β/α Ratio Predicts Response of Pancreatic Cancer Cells to Estrogens and Phytoestrogens

Journal of Surgical Research

Volumn 140, Issue 1, 2007, Pages 55-66

  Konduri, Srivani ^a   Schwarz, Roderich E ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

antiproliferative effects of ER modulators; estrogen receptor ; estrogen receptor expression; pancreatic cancer

Indexed keywords

4 HYDROXYTAMOXIFEN; COUMESTROL; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GEMCITABINE; GENISTEIN; SULFORHODAMINE B;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; GROWTH STIMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; COUMESTROL; DEOXYCYTIDINE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS, NON-STEROIDAL; GENISTEIN; HUMANS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; TAMOXIFEN;

EID: 34247558562     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.10.015     Document Type: Article

References (73)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA-Cancer J Clin 56 (2006) 106
2. Cameron J.L., Riall T.S., Coleman J., et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 244 (2006) 10
3. Fong Y., Gonen M., Rubin D., et al. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 242 (2005) 540
4. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403
5. Andren-Sandberg A., Hoem D., and Backman P.L. Other risk factors for pancreatic cancer: hormonal aspects. Ann Oncol 10 Suppl 4 (1999) 131
6. Schwarz R.E., Donohue C.A., Sadava D., et al. Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: Implications for monotherapy and combination treatment. Cancer Lett 189 (2003) 59
7. Greenway B., Iqbal M.J., Johnson P.J., et al. Oestrogen receptor proteins in malignant and fetal pancreas. Br Med J (Clin Res Ed) 283 (1981) 751
8. Pousette A., Carlstrom K., Skoldefors H., et al. Purification and partial characterization of a 17 β-estradiol-binding macromolecule in the human pancreas. Cancer Res 42 (1982) 633
9. Benz C., Hollander C., and Miller B. Endocrine-responsive pancreatic carcinoma: Steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 46 (1986) 2276
10. Poston G.J., Townsend Jr. C.M., Rajaraman S., et al. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 5 (1990) 151
11. Selvan R.S., Metzgar R.S., and Petrow V. Growth modulatory effects of some 6-methylenic steroids on human and hamster pancreatic adenocarcinoma cells in vitro. Drug Des Discov 9 (1992) 119
12. Theve N.O., Pousette A., and Carlstrom K. Adenocarcinoma of the pancreas-a hormone sensitive tumor?. A preliminary report on Nolvadex treatment. Clin Oncol 9 (1983) 193
13. Wong A., Chan A., and Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 71 (1987) 749
14. Keating J.J., Johnson P.J., Cochrane A.M., et al. A prospective randomized controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 60 (1989) 789
15. Wong A., and Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer 71 (1993) 2200
16. Rosenberg L., Barkun A.N., Denis M.H., et al. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75 (1995) 23
17. Horimi T., Takasaki M., Toki A., et al. The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. Hepatogastroenterology 43 (1996) 1225
18. Wenger F.A., Jacobi C.A., Siderow A., et al. Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen. Chirurg 70 (1999) 694
19. Schumacher G., Kataoka M., Roth J.A., et al. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5 (1999) 493
20. Sumi C., Brinck-Johnsen T., and Longnecker D.S. Inhibition of a transplantable pancreatic carcinoma by castration and estradiol administration in rats. Cancer Res 49 (1989) 6687
21. Kuramoto M., Yamashita J., and Ogawa M. Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells. Cancer 75 (1995) 1263
22. Lhoste E.F., Roebuck B.D., Brinck-Johnsen T., et al. Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Fischer rats. Carcinogenesis 8 (1987) 699
23. Sumi C., Longnecker D.S., Roebuck B.D., et al. Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine. Cancer Res 49 (1989) 2332
24. Longnecker D.S., and Sumi C. Effects of sex steroid hormones on pancreatic cancer in the rat. Int J Pancreatol 7 (1990) 159
25. Abe M., Yamashita J., and Ogawa M. Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation. Cancer 88 (2000) 2000
26. Targarona E.M., Pons M.D., Gonzalez G., et al. Is exocrine pancreatic cancer a hormone-dependent tumor?. A study of the existence of sex hormone receptors in normal and neoplastic pancreas. Hepatogastroenterology 38 (1991) 165
27. Taylor O.M., Teasdale J., Cowen P.N., et al. Classical oestrogen receptor is not detectable in pancreatic adenocarcinoma. Br J Cancer 66 (1992) 503
28. Ollayos C.W., Riordan G.P., and Rushin J.M. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med 118 (1994) 630
29. Adami H.O., Persson I., Hoover R., et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44 (1989) 833
30. Baum A., Kamino K., Son W.C., et al. Lack of influence of diethylstilbestrol on induced pancreatic ductal carcinomas in Syrian hamsters. Exp Toxicol Pathol 47 (1995) 117
31. Wenger F.A., Kilian M., Mautsch I., et al. Influence of octreotide and tamoxifen on tumor growth and liver metastasis in N-nitroso-bis(2-oxopropyl)amine-induced pancreatic cancer in Syrian hamsters. Horm Res 54 (2000) 74
32. Crowson M.C., Dorrell A., Rolfe E.B., et al. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol 12 (1986) 335
33. Swarovsky B., Wolf M., Havemann K., et al. Tamoxifen or cyproterone acetate in combination with buserelin are ineffective in patients with pancreatic adenocarcinoma. Oncology 50 (1993) 226
34. Bakkevold K.E., Pettersen A., Arnesjo B., et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 77 (1990) 725
35. Taylor O.M., Benson E.A., McMahon M.J., and The Yorkshire Gastrointestinal Tumor Group. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br J Surg 80 (1993) 384
36. Katzenellenbogen B.S., and Katzenellenbogen J.A. Estrogen receptor transcription and transactivation: Estrogen receptor α and estrogen receptor β: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2 (2000) 335
37. Friess H., Buchler M., Kiesel L., et al. LH-RH receptors in the human pancreas. Basis for antihormonal treatment in ductal carcinoma of the pancreas. Int J Pancreatol 10 (1991) 151
38. Singh S., Baker P.R., Poulsom R., et al. Expression of estrogen receptor and estrogen-inducible genes in pancreatic cancer. Br J Surg 84 (1997) 1085
39. Hollande E., Fanjul M., Houti N., et al. Expression of estrogen receptors during growth of human pancreatic adenocarcinoma cells (Capan-1)-relationship with differentiation. In Vitro Cell Dev Biol Anim 34 (1998) 593
40. Iwao K., Miyoshi Y., Ooka M., et al. Quantitative analysis of estrogen receptor-α and -β messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. Cancer Lett 170 (2001) 91
41. Kuiper G.G., Lemmen J.G., Carlsson B., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139 (1998) 4252
42. An J., Tzagarakis-Foster C., Scharschmidt T.C., et al. Estrogen receptor β-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 276 (2001) 17808
43. Roger P., Sahla M.E., Makela S., et al. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 61 (2001) 2537
44. Knowlden J.M., Gee J.M., Robertson J.F., et al. A possible divergent role for the estrogen receptor α and β subtypes in clinical breast cancer. Int J Cancer 89 (2000) 209
45. Cullen R., Maguire T.M., McDermott E.W., et al. Studies on estrogen receptor-α and -β mRNA in breast cancer. Eur J Cancer 37 (2001) 1118
46. Dotzlaw H., Leygue E., Watson P.H., et al. Estrogen receptor-β messenger RNA expression in human breast tumor biopsies: Relationship to steroid receptor status and regulation by progestins. Cancer Res 59 (1999) 529
47. Jarvinen T.A., Pelto-Huikko M., Holli K., et al. Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156 1 (2000) 29-35
48. Leygue E., Dotzlaw H., Watson P.H., et al. Expression of estrogen receptor β1, β2, and β5 messenger RNAs in human breast tissue. Cancer Res 59 (1999) 1175
49. Speirs V., Malone C., Walton D.S., et al. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 59 (1999) 5421
50. Campbell-Thompson M., Lynch I.J., and Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res 61 (2001) 632
51. Foley E.F., Jazaeri A.A., Shupnik M.A., et al. Selective loss of estrogen receptor β in malignant human colon. Cancer Res 60 (2000) 245
52. Fiorelli G., Picariello L., Martineti V., et al. Functional estrogen receptor β in colon cancer cells. Biochem Biophys Res Commun 261 (1999) 521
53. Arai N., Strom A., Rafter J.J., et al. Estrogen receptor β mRNA in colon cancer cells: Growth effects of estrogen and genistein. Biochem Biophys Res Commun 270 (2000) 425
54. Latil A., Bieche I., Vidaud D., et al. Evaluation of androgen, estrogen (ER α and ER β), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61 (2001) 1919
55. Ito T., Tachibana M., Yamamoto S., et al. Expression of estrogen receptor (ER-α and ER-β) mRNA in human prostate cancer. Eur Urol 40 (2001) 557
56. Leav I., Lau K.M., Adams J.Y., et al. Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159 (2001) 79
57. Lau K.M., LaSpina M., Long J., et al. Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 60 (2000) 3175
58. Lau K.M., Mok S.C., and Ho S.M. Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U.S.A. 96 (1999) 5722
59. Pujol P., Rey J.M., Nirde P., et al. Differential expression of estrogen receptor-α and -β messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58 (1998) 5367
60. Utsunomiya H., Suzuki T., Harada N., et al. Analysis of estrogen receptor α and β in endometrial carcinomas: correlation with ER β and clinicopathologic findings in 45 cases. Int J Gynecol Pathol 19 (2000) 335
61. Omoto Y., Kobayashi Y., Nishida K., et al. Expression, function, and clinical implications of the estrogen receptor β in human lung cancers. Biochem Biophys Res Commun 285 (2001) 340
62. Hall J.M., Couse J.F., and Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 17 (2001) 17
63. Jones P.S., Parrott E., and White I.N. Activation of transcription by estrogen receptor α and β is cell type- and promoter-dependent. J Biol Chem 274 (1999) 32008
64. Pettersson K., Delaunay F., and Gustafsson J.A. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene 19 (2000) 4970
65. Hall J.M., and McDonnell D.P. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 (1999) 5566
66. Paech K., Webb P., Kuiper G.G., et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277 (1997) 1508
67. Katzenellenbogen B.S., Choi I., Delage-Mourroux R., et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 74 (2000) 279
68. Dutertre M., and Smith C.L. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 295 (2000) 431
69. Balabhadrapathruni S., Thomas T.J., Yurkow E.J., et al. Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells. Oncol Rep 7 (2000) 3
70. Morito K., Hirose T., Kinjo J., et al. Interaction of phytoestrogens with estrogen receptors α and β. Biol Pharm Bull 24 (2001) 351
71. Lyn-Cook B.D., Stottman H.L., Yan Y., et al. The effects of phytoestrogens on human pancreatic tumor cells in vitro. Cancer Lett 142 (1999) 111
72. Bausero P., Ben-Mahdi M., Mazucatelli J., et al. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol 279 (2000) H2033
73. Curtis S.W., Washburn T., Sewall C., et al. Physiological coupling of growth factor and steroid receptor signaling pathways: Estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci U.S.A. 93 (1996) 12626